Injectables That Are Coming in 2026 and Beyond

Finding the right injectable has never been more nuanced. With scientific advancements driving innovation at a rapid pace, 2025 and 2026 will introduce a new class of products designed to deliver results faster, last longer and look even more natural. From short-duration neurotoxins to next-generation fillers, here’s a look at what’s coming next to the syringe.

Featured Experts

• Terrence Keaney, MD is a board-certified dermatologist in Arlington, VA
• Sachin Shridharani, MD is a board-certified plastic surgeon in New York
• Rui Avelar, MD is the chief medical officer at Evolus
• Michel Brousset is the CEO at Waldencast

TrenibotE (Allergan)

Type: Neurotoxin

What sets it apart: Think of this as Botox’s fast, short-lived cousin. “TrenibotulinumtoxinE (TrenibotE) is a first-in-class Type E, fast-acting, short-duration neurotoxin,” says Arlington, VA dermatologist Terrence Keaney, MD. “Results are seen as early as eight hours after treatment and wear off in two to three weeks.”

That short window might actually be the selling point. “Many new patients are hesitant about looking unnatural,” Dr. Keaney says. “A product like TrenibotE that works quickly but fades fast could help people test-drive neurotoxins without committing to months of results.”

ETA: Allergan says TrenibotE is currently under FDA review for frown lines, with expected commercialization in 2026.

Relfydess (Galderma)

Type: Neurotoxin

What sets it apart: “Relfydess is one of the first ready-to-use liquid toxins in the world,” says New York plastic surgeon Sachin Shridharani, MD. “It’s made from a new strain of botulinum toxin type A, different from all others on the market, which gives it stability and makes it easy to inject.”

The result? Faster onset and longer-lasting results. “It’s the modern neurotoxin, for the modern patient, in the modern world,” Dr. Shridharani adds.

ETA: Already approved in Europe and several other countries, U.S. FDA review is underway.

Evolysse Sculpt (Evolus)

Type: Hyaluronic acid filler

What sets it apart: Evolus, the brand behind Jeuveau, is expanding its filler line (which currently includes Evolysse Smooth and Form) with Evolysse Sculpt, designed for restoring mid-face volume. “It’s the most structured product in the Evolysse collection and, pending approval, will be the only treatment for mid-face volume loss made with Cold-X Technology, which helps preserve the HA molecule’s natural structure,” says Rui Avelar, MD, chief medical officer at Evolus.

ETA: Expected FDA approval in the second half of 2026.

Saypha MagIQ (Obagi Medical)

Type: Hyaluronic acid filler

What sets it apart: Obagi (best known for its dermatologist-dispensed skin care) is expanding into injectables with Saypha MagIQ, developed in partnership with Austria’s Croma-Pharma. Early trials on 270 patients showed consistent, natural-looking results through 48 weeks.

“This allows us to serve both providers and patients more completely,” said Waldencast CEO Michel Brousset in a statement. “It’s about creating a more integrated approach to beauty and skin health.”

ETA: FDA approved in September 2025, with a U.S. launch expected in 2026.

As innovation in injectables accelerates, one thing is clear: the next wave isn’t just about freezing movement or filling lines, it’s about creating results that feel more natural, flexible and true to the individual. Expect 2026 to bring even more precision, personalization and possibilities to the syringe.